{
    "root": "455f5a7a-2c80-4b4b-83a7-e3383c559d7d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "MESNEX",
    "value": "20191221",
    "ingredients": [
        {
            "name": "MESNA",
            "code": "NR7O1405Q9"
        },
        {
            "name": "LACTOSE",
            "code": "J2B2A4N98G"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O"
        }
    ],
    "indications": "MESNEX is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. \n                  \n                     Limitation of Use: \n                  \n                  MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia.",
    "contraindications": "MESNEX may be given on a fractionated dosing schedule of three bolus intravenous injections or a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below. The dosing schedule should be repeated on each day that ifosfamide is administered.  When the dosage of ifosfamide is adjusted, the ratio of MESNEX to ifosfamide should be maintained. ( 2 ) Intravenous Dosing Schedule: 0 Hours 4 Hours 8 Hours Ifosfamide 1.2 g/m 2 -- -- MESNEX injection 240 mg/m 2 240 mg/m 2 240 mg/m 2 Intravenous and Oral Dosing Schedule: 0 Hours 2 Hours 6 Hours Ifosfamide 1.2 g/m 2 -- -- MESNEX injection 240 mg/m 2 -- -- MESNEX tablets -- 480 mg/m 2 480 mg/m 2 Maintain sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of hematuria. ( 2.3 )",
    "warningsAndPrecautions": "MESNEX (mesna) injection 100 mg/mL\n                  \n                     \n                        •NDC 0338-1305-01 1 g Multidose Vial, Box of 1 vial of 10 mL\n                     \n                        •NDC 0338-1305-03 1 g Multidose Vial, Box of 10 vials of 10 mL\n                     \n                         Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]\n                  \n                  If MESNEX is co-administered with ifosfamide, refer to the ifosfamide prescribing information for safe handling instructions.\n                  MESNEX (mesna) tablets\n                  \n                     \n                        •NDC 67108-3565-9 400 mg scored tablets packaged in box of 10 tablets\n                     \n                         Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]",
    "adverseReactions": "MESNEX is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see Warnings and Precautions (5.1)]."
}